Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?

Clinical Endocrinology

Volumn 76, Issue 2, 2012, Pages 179-181

  Landau, D ^a   Tsakok, T ^a   Aylwin, S ^b   Hughes, S ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; HUMAN; HYPOGONADISM; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; PROSTATECTOMY; PUBLICATION; RECURRENCE RISK; RISK BENEFIT ANALYSIS;

ANDROGEN ANTAGONISTS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84855427650     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04233.x     Document Type: Article

References (25)

1. Jemal, A., Siegel, R., Xu, J., et al. (2010) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277-300.
2. Huggins, C., (1942) Effect of orchidectomy and irradiation on cancer of the prostate. Annals of Surgery, 115, 1192-2000.
3. Morote, J., Orsola, A., Planas, J., et al. (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Journal of Urology, 178, 1290-1295. (Pubitemid 47368393)
4. Meyer, F., Moore, L., Bairati, I., et al. (1999) Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. Journal of Urology, 162, 2024-2028.
5. Messing, E.M., Manola, J., Yao, J., et al. (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet Oncology, 7, 472-479. (Pubitemid 43779173)
6. Bolla, M., Van Tienhoven, G., Warde, P., et al. (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet Oncology, 11, 1066-1073.
7. Pilepich, M.V., Winter, K., Lawton, C.A., et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. International Journal of Radiation Oncology, Biology, Physics, 61, 1285-1290. (Pubitemid 40470408)
8. Bhasin, S., Cunningham, G.R., Hayes, F.J., et al. (2010) Testosterone therapy in men with androgen deficiency syndrome: an Endocrine Society Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536-2559.
9. Morgentaler, A., (2009) Testosterone therapy in men with prostate cancer: scientific and ethical considerations. Journal of Urology, 181, 972-979.
10. Wheeler, M.J., &, Barnes, S.C., (2008) Measurement of testosterone in the diagnosis of hypogonadism in the ageing male. Clinical Endocrinology, 69, 515-525.
11. Nieschlag, E., (2006) Testosterone treatment comes of age: new options for hypogonadal men. Clinical Endocrinology, 65, 275-281.
12. Bassil, N., Alkaade, S., &, Morley, J.E., (2009) The benefits and risks of testosterone replacement therapy: a review. Therapeutics and Clinical Risk Management, 5, 427-448.
13. Grossman, M., &, Zajac, J.D., (2011) Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clinical Endocrinology, 74, 289-293.
14. Padula, G.D., Zelefsky, M.J., Venkatraman, E.S., et al. (2002) Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics, 52, 439-443. (Pubitemid 34170848)
15. Bolona, E.R., Uraga, M.V., &, Haddard, R.M., (2007) Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings, 82, 20-28. (Pubitemid 46036318)
16. Morales, A., (2002) Androgen replacement therapy and prostate safety. European Urology, 41, 113-120. (Pubitemid 35428875)
17. Kaufman, J.M., &, Graydon, R.J., (2004) Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. Journal of Urology, 172, 920-922. (Pubitemid 39096423)
18. Agarwal, P.K., &, Oefelein, M.G., (2005) Testosterone replacement therapy after primary treatment for prostate cancer. Journal of Urology, 173, 533-536.
19. Khera, M., Grober, E.D., Najari, B., et al. (2009) Testosterone replacement therapy following radical prostatectomy. The Journal of Sexual Medicine, 6, 1165-1170.
20. Sathyamoorthy, K., Stein, M., Mohammed, O., et al. (2010) Testosterone replacement therapy in high risk patients following radical prostatectomy [abstract 1498]. Journal of Urology, 183 (Suppl), e577.
21. Nabulsi, O., Tal, R., Gotto, G., et al. (2008) Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy. Journal of Urology, 179 (Suppl), 426-427.
22. Sarosdy, M.F., (2007) Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer, 109, 536-541. (Pubitemid 46190961)
23. Morales, A., Black, A.M., &, Emerson, L.E., (2009) Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU International, 103, 62-64.
24. Davila, H.H., Arison, C.N., Hall, M.K., et al. (2008) Analysis of the PSA response after testosterone supplementation in patients who previously received management for their localized prostate cancer [abstract]. Journal of Urology, 179 (Suppl), 428.
25. Leibowitz, R., Dorff, T.B., Tucker, S., et al. (2010) Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU International, 105, 1397-1401.